Vienna
Austria
95
2025-12-25
The entities that hold a legal rights for patent applications filed by inventor Scheiflinger Friedrich:
Friedrich Scheiflinger from Vienna, AT has applied for patents for these inventions. The list has both pending applications and granted patents:
TREATMENT OF COAGULATION DISEASE BY ADMINISTRATION OF RECOMBINANT VWF
#2 | 2024-03-28GENE THERAPY OF HEMOPHILIA B USING VIRAL VECTORS ENCODING RECOMBINANT FIX VARIANTS WITH INCREASED EXPRESSION
#3 | 2023-07-06VIRAL VECTORS ENCODING RECOMBINANT FVIII VARIANTS WITH INCREASED EXPRESSION FOR GENE THERAPY OF HEMOPHILIA A
#4 | 2022-08-11USE OF RECOMBINANT ADAMTS13 FOR TREATING SICKLE CELL DISEASE
#5 | 2022-07-07VIRAL VECTORS ENCODING RECOMBINANT FVIII VARIANTS WITH INCREASED EXPRESSION FOR GENE THERAPY OF HEMOPHILIA A
#6 | 2022-02-17Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
#7 | 2022-01-06ADAMTS13-CONTAINING COMPOSITIONS HAVING THROMBOLYTIC ACTIVITY
#8 | 2021-05-06COMPOSITIONS COMPRISING ADAMTS13 FOR USE IN METHODS FOR THE RECANALIZATION OF OCCLUDED BLOOD VESSELS IN AN INFARCTION
#9 | 2021-05-06VIRAL VECTORS ENCODING RECOMBINANT FIX WITH INCREASED EXPRESSION FOR GENE THERAPY OF HEMOPHILIA B
#10 | 2020-09-17Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
#11 | 2020-08-06Gene therapy of hemophilia B using viral vectors encoding recombinant fix variants with increased expression
#12 | 2019-11-07Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
#13 | 2019-08-01Compositions of human prothrombin and activated factor X for improving hemostasis in the treatment of bleeding disorders
#14 | 2019-07-25Biologically active peptides
#15 | 2019-07-04Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
#16 | 2019-06-27Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
#17 | 2019-05-30ADAMTS13-containing compositions having thrombolytic activity
#18 | 2019-05-09TFPI inhibitors and methods of use
#19 | 2018-11-29Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia B
#20 | 2018-06-07TFPI inhibitors and methods of use
#21 | 2018-03-15TFPI inhibitors and methods of use
#22 | 2017-08-17Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
#23 | 2017-08-10RECOMBINANT CO-EXPRESSION OF VITAMIN K EPOXIDE REDUCTASE SUBUNIT 1 TO IMPROVE VITAMIN K DEPENDENT PROTEIN EXPRESSION
#24 | 2017-08-10Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
#25 | 2017-06-22TFPI inhibitors and methods of use
#26 | 2017-06-22Biologically active peptides
#27 | 2017-06-08TFPI inhibitors and methods of use
#28 | 2017-03-09Composition Exhibiting a von Willebrand Factor (vWF) Protease Activity Comprising a Polypeptide Chain with the Amino Acid Sequence AAGGILHLELLV
#29 | 2017-02-09Peptides and methods of use
#30 | 2016-06-30TREATMENT OF COAGULATION DISEASE BY ADMINISTRATION OF RECOMBINANT VWF
#31 | 2016-05-12Factor VIIa-polysialic acid conjugates having prolonged in vivo half-life
#32 | 2016-03-03Biologically active peptides
#33 | 2015-09-17COMPOSITIONS OF HUMAN PROTHROMBIN AND ACTIVATED FACTOR X FOR IMPROVING HEMOSTASIS IN THE TREATMENT OF BLEEDING DISORDERS
#34 | 2015-09-03Peptides and methods of use
#35 | 2015-08-20TFPI inhibitors and methods of use
#36 | 2015-06-11Anti-MIF immunohistochemistry
#37 | 2015-02-05Biologically active peptides
#38 | 2015-01-22ANTI MIF ANTIBODIES
#39 | 2014-11-13Composition exhibiting a von Willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
#40 | 2014-09-25Characterization of CHO-MIF gene and protein, and use thereof
#41 | 2014-09-04OxMIF as a diagnostic marker
#42 | 2014-07-03FACTOR VIIA-POLYSIALIC ACID CONJUGATES HAVING PROLONGED IN VIVO HALF-LIFE
#43 | 2014-02-20Methods and systems for screening compositions comprising non-anticoagulant sulfated polysaccharides
#44 | 2014-02-20Methods for Treating Bleeding Disorders
#45 | 2013-11-14Methods and compositions for treating bleeding disorders
#46 | 2013-10-17TFPI inhibitors and methods of use
#47 | 2013-10-10APTAMERS TO TISSUE FACTOR PATHWAY INHIBITOR AND THEIR USE AS BLEEDING DISORDER THERAPEUTICS
#48 | 2013-10-03TFPI inhibitors and methods of use
#49 | 2013-09-26TFPI inhibitors and methods of use
#50 | 2013-07-25Polymer von Willebrand factor-conjugates
#51 | 2013-06-06PROCEDURE FOR THE GENERATION OF A HIGH PRODUCER CELL LINE FOR THE EXPRESSION OF A RECOMBINANT ANTI-CD34 ANTIBODY
#52 | 2013-05-30ADAMTS13-containing compositions having thrombolytic activity
#53 | 2013-01-10Von willebrand factor- and factor VIII-polymer conjugates having a releasable linkage
#54 | 2012-12-13Treatment of coagulation disease by administration of recombinant VWF
#55 | 2012-12-13DETECTION OF CIRCULATING ADAMTS13-ANTIBODY COMPLEXES
#56 | 2012-06-07Von Willebrand factor- and factor VIII-polymer conjugates having a releasable linkage
#57 | 2012-05-31Polymer-von Willebrand factor-conjugates
#58 | 2012-03-29Procoagulant peptides
#59 | 2012-02-02TFPI inhibitors and methods of use
#60 | 2011-10-06Methods and compositions for treating bleeding disorders
#61 | 2011-08-25FVIII-independent FIX-mutant proteins for hemophilia a treatment
#62 | 2011-07-14Methods and compositions for treating bleeding disorders
#63 | 2011-05-19Factor VIII polypeptide having factor VIII:C activity
#64 | 2011-05-12Polymer-von Willebrand factor-conjugates
#65 | 2011-05-12Method for identifying a non-anticoagulant sulfated polysaccharide which enhances blood coagulation dependence on FXI
#66 | 2010-10-28Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
#67 | 2010-10-14Anti MIF antibodies
#68 | 2010-07-27Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
#69 | 2010-07-08TFPI inhibitors and methods of use
#70 | 2010-07-01Preparations based on fibrinogen and sulfated polysaccharides
#71 | 2010-01-28Procoagulant peptides
#72 | 2009-10-22Immunoadsorption of anti-von Willebrand factor cleaving protease antibodies
#73 | 2009-09-03Procedure for the generation of a high producer cell line for the expression of a recombinant anti-CD34 antibody
#74 | 2009-09-03Anti MIF Antibodies
#75 | 2009-08-13Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
#76 | 2009-07-09CHEMICALLY MODIFIED FACTOR IX
#77 | 2009-01-15Composition exhibiting a von Willebrand Factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
#78 | 2008-09-25von Willebrand factor- and factor VIII-polymer conjugates having a releasable linkage
#79 | 2008-09-11Factor VIIa-polysialic acid conjugate having prolonged in vivo half-life
#80 | 2008-09-11Method of treating a patient suffering from a bleeding disorder comprising administering an antibody against the A3-C1 of FVIII
#81 | 2008-09-04FIX-Mutant Proteins for Hemophilia B Treatment
#82 | 2008-09-04FVIII-independent FIX-mutant proteins for hemophilia A treatment
#83 | 2008-07-24Composition exhibiting a von Willebrand Factor (vWF) protease activity with the amino acid sequence AAGGILHLELLV
#84 | 2008-07-24Highly phosphorylated and sulfated recombinant factor IX
#85 | 2007-10-18Highly phosphorylated and sulfated recombinant factor IX
#86 | 2007-01-18ADAMTS13-containing compositions having thrombolytic activity
#87 | 2006-08-31Nucleic acids encoding vitamin K expoxide reductase subunit 1 and vitamin K dependent protein expression and methods of using same
#88 | 2006-07-20Factor VIII polypeptide having factor VIII:C activity
#89 | 2006-07-20Polymer-factor VIII-von Willebrand factor-conjugates
#90 | 2006-04-25Factor IX/factor IXa activating antibodies and antibody derivatives
#91 | 2005-12-01Composition exhibiting a von Willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
#92 | 2005-09-08Factor IX/factor IXa activating antibodies and antibody derivatives
#93 | 2005-08-09Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
#94 | 2005-04-07Factor VII polypeptide having factor VII:C activity
#95 | 2005-03-17Factor IXa specific antibodies displaying factor VIIIa like activity
29683 ⎘